MiMedx Group, Inc - Common Stock (NQ:MDXG)

3.310 +0.030 (+0.91%)

Delayed Quote Updated: 4:00 PM EST, Nov 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MiMedx Group, Inc - Common Stock

< Previous 1 2 3 4 Next >

MiMedx Group (NASDAQ: MDXG) Reports Q1 2023 Financial Results Showing 21.7% Sales Growth

May 03, 2023

MiMedx Group, Inc. (NASDAQ: MDXG) is engaged as a biotechnology company that is focused as a placental biologics developer to

Via Spotlight Growth

Veritone, Samsara, Lexicon Pharmaceuticals And Other Big Stocks Moving Higher On Friday ↗

March 03, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

January 04, 2023

Via Benzinga

BioStem Aims To Stay Ahead Of Competition Through Its Unique Processes And Versatile Offerings In Wound Healing ↗

December 08, 2022

The human body has an amazing ability to heal itself, but the pace and extent of healing can vary dramatically from case to case, depending on the nature of the injury, site and the extent of tissue...

Via Benzinga

Recap: MiMedx Group Q4 Earnings ↗

February 28, 2022

MiMedx Group (NASDAQ:MDXG) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Earnings Scheduled For February 28, 2022 ↗

February 28, 2022

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...

Via Benzinga

Earnings Scheduled For November 2, 2021 ↗

November 02, 2021

Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion. •...

Via Benzinga

Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

November 15, 2022

EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END

Via FinancialNewsMedia

Nikola, Bed Bath & Beyond And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗

September 14, 2022

U.S. stock futures traded higher this morning ahead of the PPI data for August. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

MiMedx Group: Q2 Earnings Insights ↗

August 02, 2022

MiMedx Group (NASDAQ:MDXG) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings MiMedx Group missed estimated...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022 ↗

October 13, 2022

Upgrades

Via Benzinga

Earnings Scheduled For August 2, 2022 ↗

August 02, 2022

Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.

Via Benzinga

Earnings Outlook For MiMedx Group ↗

August 01, 2022

MiMedx Group (NASDAQ:MDXG) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that MiMedx Group...

Via Benzinga

MiMedx Group's Return on Invested Capital Insights ↗

May 13, 2022

Benzinga Pro data, MiMedx Group (NASDAQ:MDXG) reported Q1 sales of $58.89 million. Earnings fell to a loss of $10.49 million, resulting in a 573.54% decrease from last quarter.

Via Benzinga

Recap: MiMedx Group Q1 Earnings ↗

May 03, 2022

MiMedx Group (NASDAQ:MDXG) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings MiMedx Group missed estimated...

Via Benzinga

Earnings Outlook For MiMedx Group ↗

May 02, 2022

MiMedx Group (NASDAQ:MDXG) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that MiMedx Group...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 14, 2021

Gainers Progenity (NASDAQ:PROG) shares increased by 17.0% to $1.1 during Tuesday's regular session. As of 12:30 EST, this security is trading at a volume of 40.5...

Via Benzinga

86 Biggest Movers From Yesterday ↗

November 04, 2021

Gainers FAT Brands Inc. (NASDAQ: FATBB) shares gained 99.2% to settle at $15.44. FAT Brands recently announced plans to acquire Fazoli’s Restaurant Chain for $130 million....

Via Benzinga

The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study ↗

September 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC)...

Via Benzinga

Mid-Afternoon Market Update: Dow Rises Over 100 Points; Itamar Medical Shares Spike Higher ↗

September 13, 2021

Toward the end of trading Monday, the Dow traded up 0.38% to 34,739.18 while the NASDAQ fell 0.27% to 15,074.10. The S&P also fell, dropping 0.07% to 4,455.53. The U.S. has...

Via Benzinga

Topics Stocks

72 Biggest Movers From Yesterday ↗

September 14, 2021

Gainers aTyr Pharma, Inc. (NASDAQ: LIFE) jumped 67% to settle at $9.15 on Monday as the company announced positive results from its Phase 1b/2a trial evaluating its lead...

Via Benzinga

Dow Set to Snap Skid, Eyes Best Day in a Month ↗

September 13, 2021

The Dow Jones Industrial Index is seeing a dramatic rebound off its five-day slump, last seen up 263 points and on track for its best single-session gain since Aug. 5.

Via Talk Markets

Topics Stocks

Why Shares of MiMedx Are Collapsing Today ↗

September 13, 2021

The company released data for two drug programs and missed its goals on both.

Via The Motley Fool

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 13, 2021

Gainers Itamar Medical (NASDAQ:ITMR) shares increased by 46.58% to $30.25 during Monday's regular session. Trading volume for Itamar Medical's stock is 2.6 million...

Via Benzinga

Mid-Day Market Update: Crude Oil Up 1%; MiMedx Group Shares Plummet ↗

September 13, 2021

Midway through trading Monday, the Dow traded up 0.80% to 34,885.46 while the NASDAQ fell 0.10% to 15,100.02. The S&P also rose, gaining 0.23% to 4,468.75. The U.S. has the...

Via Benzinga

Topics Stocks

45 Stocks Moving In Monday's Mid-Day Session ↗

September 13, 2021

Gainers Aterian, Inc. (NASDAQ: ATER) jumped 54.1% to $18.18. Investor presentation released on Friday is now circulating on news outlets. Itamar Medical Ltd. (NASDAQ: ITMR)...

Via Benzinga

Mid-Morning Market Update: Markets Mixed; UK Terminates Valneva's COVID-19 Vaccine Contract ↗

September 13, 2021

Following the market opening Monday, the Dow traded up 0.61% to 34,817.26 while the NASDAQ fell 0.40% to 15,055.69. The S&P also rose, gaining 0.05% to 4,460.84. The U.S. has...

Via Benzinga

Topics Stocks

Why MiMedx Shares Are Diving Today ↗

September 13, 2021

MiMedx Group Inc (NASDAQ: MDXG) is trading significantly lower Monday after the company announced top-line results from two late-stage musculoskeletal clinical trials. ...

Via Benzinga

Mimedx Stock Plunges After Disappointing Data From Musculoskeletal Trials ↗

September 13, 2021

MiMedx Group Inc (NASDAQ: MDXG) stock dropped after announcing top-line results from two musculoskeletal trials of micronized dehydrated Human Amnion Chorion...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

September 13, 2021

Gainers Itamar Medical (NASDAQ:ITMR) shares moved upwards by 44.37% to $29.8 during Monday's pre-market session. The market value of their outstanding shares is at $...

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.